Clinical Characteristics of Peptic Ulcer Disease & its Pharmacological Management in Primary Care
DOI:
https://doi.org/10.3329/mediscope.v10i1.65408Keywords:
Peptic ulcer, Clinical feature PPIsAbstract
Background: Peptic ulcer diseases (PUD) are common conditions reported in daily clinical practice. Proton pump inhibitors (PPIs) are the most potent pharmacological inhibitors of gastric acid secretion.
Aims & objectives: This study aimed to evaluate & understand the clinical presentation and management of PUD with PPIs in general practice.
Methods: This prospective study was conducted on 150 diagnosed cases of PUD patients in a single center of private practice in rural areas from February 2022 to August 2022. Patients were enrolled by following inclusion & exclusion criteria with informed written consent. Eight (08) weeks after the completion of treatment by giving PPIs, a repeat endoscopy was done to see the improvement of healing of the ulcer. All data were collated and results were expressed in percentages which are illustrated in different tables & figures.
Results: Among 150 endoscopically diagnosed PUD patients major age group was 31-40 years (50%) of both sexes where the male (58.66%) were more predominant. Abdominal pain (82%), heartburn (56.66%), etc were the main clinical symptoms of the patients who were referred for endoscopy. After confirming the diagnosis, PPIs were given to the patients. Esomeprazole (34.66%), lansoprazole (22%), pantoprazole (18.66%), etc were prescribed frequently. After 8 weeks of treatment, repeat endoscopy revealed that the ulcer was completely healed in 65.33% of patients whereas only 6.66% had no improvement.
Conclusion: The majority of the patient are almost cured of PUD by receiving various types of PPIs which are very effective drugs for healing peptic ulcer disease.
Mediscope 2023;10(1): 22-30
Downloads
36
53
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Mohammed Khorshed Alam, Baishakhi Islam
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in the Mediscope agree to the following terms that:
- Authors retain copyright and grant Mediscope the right of first publication of the work.
Articles in Mediscope are licensed under a Creative Commons Attribution 4.0 International License CC BY-4.0. This license permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Authors are able to enter into separate, additional contractual arrangements for the distribution of the journal’s published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted to post their work online (e.g., in institutional repositories or on their website) as it can lead to productive exchanges, as well as greater citation of published work.